Avidity Partners Management LP 13D and 13G filings for Syros Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 10:10 am Sale | 2024-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Avidity Partners Management LP | 2,048,020 7.600% | -809,553 (-28.33%) | Filing |
| 2024-11-14 5:28 pm Purchase | 2024-09-30 | 13G | Syros Pharmaceuticals, Inc. SYRS | Avidity Partners Management LP | 2,857,573 9.900% | 195,367 (+7.34%) | Filing |
| 2024-02-13 8:22 pm Purchase | 2023-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Avidity Partners Management LP | 2,662,206 9.900% | 472,487 (+21.58%) | Filing |
| 2023-02-14 4:07 pm Purchase | 2022-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Avidity Partners Management LP | 2,189,719 9.900% | 69,719 (+3.29%) | Filing |
| 2022-09-20 4:35 pm Purchase | 2022-09-16 | 13G | Syros Pharmaceuticals, Inc. SYRS | Avidity Partners Management LP | 2,120,000 9.900% | 2,120,000 (New Position) | Filing |